tarlatamab
amgen
['lung', 'dll3', 'tarlatamab']
randomized phase 3 study of tarlatamab, a dll3-targeting bispecific t-cell engager (bite), compared to standard of care in patients with relapsed small cell lung cancer (dellphi-304). #asco23 #asco2023 #medtwitter #oncology #news 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News